Healing of the bone with anti-fracture drugs.
Fracture healing is a complex physiological process. As impaired fracture healing is more frequent in osteoporotic subjects, anti-osteoporotic drugs could have some impact on this process. Areas covered: We reviewed the current literature to evaluate the effects of these drugs on fracture healing and their potential role in supporting this process, especially when impaired. A PubMed/Medline search was undertaken combining the terms 'fracture healing', 'anti-resorptive drugs', 'anabolic agents', 'anti-osteoporotic drugs'. Expert opinion: As clinical evidence on the role of anti-osteoporotic drugs in the process of fracture healing consists mainly of case reports or studies with a relatively small number of patients, large randomized clinical trials are needed in order to extend to the human setting the promising results on these agents as inductors or co-adjuvants of bone healing derived from animal studies.
a Department of Surgery and Translational Medicine , University of Florence , Florence , Italy.
Letizia
L
Vannucci
a Department of Surgery and Translational Medicine , University of Florence , Florence , Italy.
Maria Luisa
ML
Brandi
D045930:Anabolic Agents / Q000627:therapeutic use; D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D002116:Calcitonin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002118:Calcium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069448:Denosumab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017102:Fracture Healing / Q000187:drug effects*; D050723:Fractures, Bone / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D019379:Teriparatide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014807:Vitamin D / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D045930:Anabolic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019379:Teriparatide; D014807:Vitamin D; D000069448:Denosumab; D002116:Calcitonin; D002118:Calcium
Anti-fracture drugs; anti-resorptive drugs; bone anabolic drugs; fracture healing; fracture healing impairment